| Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th |
MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum. |
globenewswire.com |
2025-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences, Inc. (SGHT) Q1 2025 Earnings Call Transcript |
Sight Sciences, Inc. (NASDAQ:SGHT ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Hannah Jefferies - Investor Relations Paul Badawi - Co-Founder & CEO Ali Bauerlein - CFO Matt Link - Chief Commercial Officer Conference Call Participants Tom Stephan - Stifel Danielle Antalffy - UBS Joanne Welsh - Citi Frank Takkinen - Lake Street Capital Markets Macauley Kilbane - William Blair David Saxon - Needham & Company Operator Good day, and thank you for standing by. Welcome to the Sight Sciences First Quarter 2025 Earnings Results Conference Call. |
seekingalpha.com |
2025-05-11 05:26:29 |
Czytaj oryginał (ang.) |
| Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-08 23:30:36 |
Czytaj oryginał (ang.) |
| Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates |
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.33 per share a year ago. |
zacks.com |
2025-05-08 22:50:43 |
Czytaj oryginał (ang.) |
| Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance |
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025. |
globenewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025 |
MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2025-04-24 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences Announces the Release of its Sustainability Report |
MENLO PARK, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its annual Sustainability Report, highlighting the Company's sustainability activities, performance and results from the last three years. |
globenewswire.com |
2025-04-23 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences Appoints Gary Burbach to its Board of Directors |
MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. |
globenewswire.com |
2025-04-22 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio |
New system features higher viscoelastic capacity and TruSync™ technology, engineered to safely synchronize surgical control and precision in implant-free, comprehensive MIGS New system features higher viscoelastic capacity and TruSync™ technology, engineered to safely synchronize surgical control and precision in implant-free, comprehensive MIGS |
globenewswire.com |
2025-04-21 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th |
MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the 24th Annual Needham Healthcare Conference being held virtually. |
globenewswire.com |
2025-03-25 18:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences, Inc. (SGHT) Q4 2024 Earnings Conference Call Transcript |
Sight Sciences, Inc. (NASDAQ:SGHT ) Q4 2024 Earnings Conference Call March 5, 2025 4:30 PM ET Company Participants Philip Trip Taylor - IR Paul Badawi - Co-Founder & CEO Alison Bauerlein - CFO Matt Link - Chief Commercial Officer Conference Call Participants Danielle Antalffy - UBS Tom Stephan - Stifel Frank Takkinen - Lake Street Capital Markets David Saxon - Needham & Company Phil Dantoin - Piper Sandler Macauley Kilbane - William Blair Operator Hello, and welcome to the Sight Sciences Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-03-06 00:06:48 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Sight Sciences (SGHT) Q4 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-03-05 21:00:50 |
Czytaj oryginał (ang.) |
| Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates |
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.22 per share a year ago. |
zacks.com |
2025-03-05 20:20:35 |
Czytaj oryginał (ang.) |
| Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance |
MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the fourth quarter and full year ended December 31, 2024 and initiated financial guidance for full year 2025. |
globenewswire.com |
2025-03-05 18:05:00 |
Czytaj oryginał (ang.) |
| Will Sight Sciences, Inc. (SGHT) Report Negative Earnings Next Week? What You Should Know |
Sight Sciences (SGHT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-26 13:05:30 |
Czytaj oryginał (ang.) |
| Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting |
A Meta-Analysis of 22 Studies, and Data from the IRIS® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant, Long-Term IOP Reduction and Medication Reduction with the OMNI® Surgical System |
globenewswire.com |
2025-02-24 18:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025 |
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024, after the market close on Wednesday, March 5, 2025. |
globenewswire.com |
2025-02-19 18:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day |
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day, in New York, NY. |
globenewswire.com |
2025-02-13 18:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options |
Budget impact analysis published in the Expert Review of Ophthalmology journal Budget impact analysis published in the Expert Review of Ophthalmology journal |
globenewswire.com |
2024-12-19 18:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference |
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Piper Sandler 36th Annual Healthcare Conference, in New York, NY. |
globenewswire.com |
2024-11-19 18:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript |
Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Macauley Kilbane - William Blair Phil Dantoin - Piper Sandler Nelson Cox - Lake Street Capital Markets Tom Stephan - Stifel Operator Thank you for standing by. My name is Janine, I will be your conference operator for today. |
seekingalpha.com |
2024-11-09 15:32:34 |
Czytaj oryginał (ang.) |
| Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Misses Revenue Estimates |
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.27 per share a year ago. |
zacks.com |
2024-11-07 22:06:14 |
Czytaj oryginał (ang.) |
| Sight Sciences to Report Third Quarter Financial Results on November 7, 2024 |
MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the third quarter ended September 30, 2024, after the market close on Thursday, November 7, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2024-10-17 20:05:00 |
Czytaj oryginał (ang.) |
| Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial |
The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits of an interventional approach for patients with dry eye disease The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits of an interventional approach for patients with dry eye disease |
globenewswire.com |
2024-10-14 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference |
MENLO PARK, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference, in New York, NY. |
globenewswire.com |
2024-08-20 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript |
Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matthew Link - Chief Commercial Officer Conference Call Participants Thomas Stephan - Stifel Joseph Conway - Needham & Company Felipe Lamar - Citi Operator Good day, and thank you for standing by. Welcome to the Sight Sciences Second Quarter 2024 Earnings Results Conference Call. |
seekingalpha.com |
2024-08-03 07:12:07 |
Czytaj oryginał (ang.) |
| Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates |
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago. |
zacks.com |
2024-08-01 23:45:42 |
Czytaj oryginał (ang.) |
| Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 |
MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the second quarter ended June 30, 2024, after the market close on Thursday, August 1, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2024-07-18 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences Announces the Release of its First Sustainability Report |
The Sustainability Report provides data for 2021 through 2023 on the Company's environmental, social, and governance initiatives The Sustainability Report provides data for 2021 through 2023 on the Company's environmental, social, and governance initiatives |
globenewswire.com |
2024-06-10 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis |
Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve. Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve. |
globenewswire.com |
2024-05-28 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma |
The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as it was in mild and moderate glaucoma. The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as it was in mild and moderate glaucoma. |
globenewswire.com |
2024-05-28 12:30:00 |
Czytaj oryginał (ang.) |
| Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript |
Sight Sciences, Inc. (NASDAQ:SGHT ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matthew Link - Chief Commercial Officer Conference Call Participants David Saxon - Needham & Company James Beers - William Blair Thomas Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to the Sight Sciences First Quarter 2024 Earnings Results Conference Call. |
seekingalpha.com |
2024-05-05 05:58:11 |
Czytaj oryginał (ang.) |
| Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates |
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.35 per share a year ago. |
zacks.com |
2024-05-02 23:20:14 |
Czytaj oryginał (ang.) |
| Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance |
MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the first quarter ended March 31, 2024, and reaffirmed financial guidance for full year 2024. |
globenewswire.com |
2024-05-02 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery |
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it received a positive jury trial verdict of $34 million associated with the patent infringement case it filed on September 16, 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, "Alcon") in the U.S. District Court for the District of Delaware. Sight Sciences asserted that Alcon's and Ivantis' sale of the Hydrus® Microstent infringed three key patents. |
globenewswire.com |
2024-04-29 12:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences to Report First Quarter Financial Results on May 2, 2024 |
MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2024-04-18 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma |
The efficacy of the three most commonly used MIGS technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared in over 100,000 glaucoma patient eyes The efficacy of the three most commonly used MIGS technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared in over 100,000 glaucoma patient eyes |
globenewswire.com |
2024-04-10 20:05:00 |
Czytaj oryginał (ang.) |
| Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting |
Clinical results demonstrate long-term efficacy of the OMNI® Surgical System for primary open-angle glaucoma and support use of TearCare® technology as a primary treatment for dry eye disease. |
globenewswire.com |
2024-04-02 20:05:00 |
Czytaj oryginał (ang.) |